BioCentury
ARTICLE | Company News

BioVeris, Baxter deal

January 8, 2007 8:00 AM UTC

BIOV received non-exclusive worldwide rights to develop BAX's Neisseria meningitidis group C vaccine as a component in new combination vaccines to prevent meningitis and sepsis. The BAX vaccine is in ...